Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (40)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by le Cotonnec, J.-Y.
Right arrow Articles by Howles, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by le Cotonnec, J.-Y.
Right arrow Articles by Howles, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 8, No. 10, pp. 1604-1611, 1993
© 1993 European Society of Human Reproduction and Embryology

research-article

Endocrinology: Comparative pharmacokinetics of two urinary human follicle stimulating hormone preparations in healthy female and male volunteers

Jean-Yves le Cotonnec1, Hervé C. Porchet, Vanya Beltrami and Colin Howles

Ares Serono, 15 bis chemin des Mines Case Postale 54, CH-1211 Geneva 20, Switzerland

Correspondence: 1To whom correspondence should be addressed

These studies were designed to compare the pharmacokinetic characteristics of a very highly purified urinary human follicle stimulating hormone (FSH-HP) preparation (sp. act. ~9000 IU FSH/mg of protein), Metrodin HP®, with a standard urinary FSH preparation Metrodin® (FSH). The two preparations were administered in a balanced, random-order, cross-over sequence as single doses of 150IU, separated by 1 week of washout to 12 female volunteers by i.v. injection and to 12 male volunteers by i.m. and s.c. routes. FSH concentrations were measured by immunoradiometric assay and by an in-vitro rat granulosa cell aromatase bioassay. After an i.v. bolus, the pharmacokinetics of the two FSH preparations were identical. Total clearance was 0.5 and 0.15 1/h respectively for immunoassay and bioassay data. Immunoassay showed that the two preparations were similar for renal clearance (0.1 1/h), volumes of distribution at steady state (9 1), distribution and terminal half-lives (2 and 17 h, respectively). After parenteral administrations, the absorption half-life of FSH was ~3 h and the apparent terminal half-life was ~1.5 days. Both preparations had relative bio-availabilities close to 100% for i.m. and s.c. administrations. Immunopurification, which results in a very highly purified FSH-HP, does not modify the pharmacokinetic properties of FSH. This study also confirmed that s.c. and i.m. doses of FSH-HP are equivalent from the pharmacokinetic and pharmacodynamic points of view.

Key words: bioassay/follicle stimulating hormone/half-life/immunoassay/pharmacokinetics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
B.C.J.M. Fauser, B.M.J.L. Mannaerts, P. Devroey, A. Leader, I. Boime, and D.T. Baird
Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency
Hum. Reprod. Update, May 1, 2009; 15(3): 309 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R. Frydman, C.M. Howles, and F. Truong
A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F(R)) with highly purified urinary FSH (Metrodin(R) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection
Hum. Reprod., March 1, 2000; 15(3): 520 - 525.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L.G. Mantovani, A. Belisari, and T.D. Szucs
Pharmaco-economic aspects of in-vitro fertilization in Italy
Hum. Reprod., April 1, 1999; 14(4): 953 - 958.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.